Best Practice No 176: Updated recommendations for HER2 testing in the UK
about
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.Clinicopathological study of male breast carcinoma: 24 years of experience.Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 statusTOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinomaGenetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.The epidermal growth factor receptor family in breast cancer.Guidance for laboratories performing molecular pathology for cancer patients.Updated UK Recommendations for HER2 assessment in breast cancer.Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testingMiniature tissue microarrays for HercepTest standardisation and analysisOverexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancerAmplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?HER2 testing in the UK: consensus from a national consultation.Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancerExternal quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.Evaluation of the current knowledge limitations in breast cancer research: a gap analysisIs TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scaleStudy of hormone receptors and epidermal growth factor expression in invasive breast cancers in a cohort of Western India.Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray.HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence.Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers.Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.Guidelines for HER2 testing in the UK.Reply to Egervari et al “IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinoma”.Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.
P2860
Q33305210-E24F8D60-C5E6-4D95-ABFE-734CDA63B9FBQ33373153-AE439611-B61C-4542-86DE-68185FBA0BCBQ33738278-C1DBA8CD-067D-45CD-BBB6-E38DFC78EFAFQ33783075-D2BDE1CD-D404-4916-B095-D591B8F81ABAQ34044864-F0C04FCD-8120-4011-8A57-4B359397A9A2Q34125003-FA9B21F6-956D-4D26-A1A5-1D02E67BB408Q34363400-6E2EC955-3D4D-492D-A306-8A4ADA7027C1Q34431280-1D4F8F53-12B5-4A9C-8FD4-7CDDE5C3037EQ35048548-5263AF3E-3EDB-4807-A8F3-49F1BC377610Q35588100-2263D991-EE88-4542-8713-3805889D22ADQ35588129-C71ADD7D-98A0-43F3-A0AD-AB8512F0B9CEQ35588545-3AB29A8F-0723-45DA-B22A-CF9F9CAB1EE2Q35588682-527D4FDE-F5B2-464A-AD44-06E8557630F2Q35588768-7B953BB4-AE0E-4ACE-8391-10695C578D0BQ35822172-D403B0DC-AC26-4F9D-84AC-DA1BEDC34208Q35893399-8B4E08F7-51A5-4F16-899E-655C75CC7C98Q35941081-0B499FF8-2B6F-44A8-BF32-9FEF82907970Q35954388-D10C22BC-DB22-4471-BE4E-CF7755E9DADFQ35954400-C378B463-1397-4873-B5C0-03EC47F04005Q35984470-9F788D43-5C39-4425-BC01-0A9FA55B890DQ36017256-1D976145-910A-4B00-A852-CA0E3B8BA591Q36140927-85A011B4-FA5D-499E-BCF2-67AB9EA96CB7Q36458747-453BDAA4-A3A9-4EB9-8F4A-8040A4F7E414Q36678664-1DEA64CD-33EA-495E-B6D6-AEC2F6C3914DQ36903127-34D75AFD-1345-4092-8236-B87454E5BEA7Q37153505-4829E453-3B6F-45CC-975A-DEA6028C9603Q37199409-BDCC287B-8AB1-4785-8B5B-BBF8B4179F3FQ37392419-52A2EC19-A5C6-4693-B580-B6A744546185Q37588232-3570233A-961C-40C4-A3CE-A0103E76C4C6Q37608440-6A7E1224-33B1-493B-8E93-2ACD5F2BA24EQ38089259-55F31078-3618-4F5B-88C8-20395AE60A8BQ38175061-A7F92132-BEFB-4864-90EE-379B40258146Q38454847-CBC844DF-D913-49A1-817B-C5B1468DA5E5Q39070009-A6008F01-748D-4252-BA33-C6D660A1E14CQ40089438-A06ACA1A-9BF6-4157-A3AD-C040C5EAABDCQ42511606-40ABBE02-2C0C-48B5-9C93-F089BCF1A46DQ43010802-2A7FFACF-BAEA-458D-885D-69BFA52B28ABQ45923839-671F6E5A-02AD-49F4-9907-C66FD5D3BD6FQ46303094-5FC8C0A6-EE27-45E5-AB13-8DB34AC6E47FQ46841926-C5308F9F-5F43-4298-85D6-608A78FDC262
P2860
Best Practice No 176: Updated recommendations for HER2 testing in the UK
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@ast
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@en
type
label
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@ast
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@en
prefLabel
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@ast
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@en
P2093
P2860
P50
P356
P1476
Best Practice No 176: Updated recommendations for HER2 testing in the UK
@en
P2093
P2860
P304
P356
10.1136/JCP.2003.007724
P407
P577
2004-03-01T00:00:00Z